Get started
Author

Kumiko Kagawa

Observed names: K Kagawa, K. Kagawa, Kagawa, Kumiko
ORCID: 0000-0001-6023-3293
Observed ORCID: 0000-0001-6023-3293
OpenAlex ID: A5002719065
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
2010 · Kyoko Takeuchi, Masahiro Abe, et al. · PLoS ONE · 141
PDF
GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)
2009 · Masahiro Hiasa, Masahiro Abe, et al. · Blood · 130
Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
2011 · Ayako Nakano, Daisuke Tsuji, et al. · PLoS ONE · 113
PDF
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
2011 · J Asano, A Nakano, et al. · Leukemia · 109
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma
2014 · M Hiasa, J Teramachi, et al. · Leukemia · 66
Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma
2007 · Shuji Ozaki, Osamu Tanaka, et al. · International Journal of Hematology · 54
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate
2012 · Ayako Nakano, Hirokazu Miki, et al. · Journal of Bioenergetics and Biomembranes · 46
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
2020 · Mohannad Ashtar, Hirofumi Tenshin, et al. · Cancers · 44
PDF
Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome
2018 · Shingen Nakamura, Momoyo Azuma, et al. · Journal of Infection and Chemotherapy · 42
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
2020 · Jumpei Teramachi, Hirofumi Tenshin, et al. · Haematologica · 36
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
2019 · Masami Iwasa, Takeshi Harada, et al. · Oncotarget · 31
PDF
Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors
2012 · A Ikegame, S Ozaki, et al. · Leukemia · 30
Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation
2018 · Kimikazu Yakushijin, Takayuki Ikezoe, et al. · Bone Marrow Transplantation · 26
Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib
2011 · Ayako Nakano, Masahiro Abe, et al. · International Journal of Hematology · 25
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib
2013 · Shingen Nakamura, Hirokazu Miki, et al. · International Journal of Hematology · 24
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma
2019 · Shuji Ozaki, Takeshi Harada, et al. · Cancers · 22
PDF
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma
2013 · Takeshi Harada, Shuji Ozaki, et al. · International Journal of Hematology · 21
Unique anti‐myeloma activity by thiazolidine‐2,4‐dione compounds with Pim inhibiting activity
2018 · Shiro Fujii, Shingen Nakamura, et al. · British Journal of Haematology · 20
PDF
Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma
2016 · Jumpei Teramachi, Masahiro Hiasa, et al. · British Journal of Haematology · 20
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
2016 · Ariunzaya Bat-Erdene, Hirokazu Miki, et al. · Oncotarget · 20
PDF
Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission
2012 · Kensuke Usuki, Saiko Kurosawa, et al. · Clinical Lymphoma Myeloma & Leukemia · 19
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
2013 · Takeshi Harada, Shuji Ozaki, et al. · PLoS ONE · 18
PDF
Targeting myeloma–osteoclast interaction with Vγ9Vδ2 T cells
2011 · Qu Cui, Hironobu Shibata, et al. · International Journal of Hematology · 16
Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL
2012 · Kumiko Kagawa, Ayako Nakano, et al. · PLoS ONE · 15
PDF
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
2022 · Takeshi Harada, Hiroto Ohguchi, et al. · Blood Advances · 12
Works count: 99
Citation count: 1,254
H-index: 20
I10-index: 30
Year
Topic
Type